NAPWA

A new, once-daily, lower dose of the protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate. darunavir (Prezista) is available on the PBS[Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs.] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. from 1 December.

To date, the recommended dose has been 600mg taken twice-a-day along with 100mg of ritonavir. But this new daily dose is just 800mg boosted with a single dose of ritonavir.

The lower dosage of both drugs appears to have a much better side effectAn unwanted effect caused by the administration of drugs. Onset may be sudden or develop over time. profile. read more »

Adrian Ogier gives the low-down on latest antiretroviralA medication or other substance which is active against retroviruses such as HIV. treatments. read more »

The Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. (PBS) has extended access to the new protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate., darunavir, now making it an option for more people. read more »

The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV, all of which are now available in Australia. read more »

A warning has been issued by Tibotec, the manufacturers of Prezista (darunavir) regarding the risk of developing drug- induced hepatitis while taking the treatment. read more »

John Daye, NAPWA's Health, Treatments & Research Portfolio Co-Convenor reports from the 15th Conference on Retroviruses and Opportunistic Infections (CROI) held in Boston, USA from 3-6 February 2008 read more »

Finding effective treatment options for people who have taken many treatments and have multiple resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant.. mutations continues to be a significant challenge for HIV clinicians, and their patients. read more »

The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports. read more »

In September 2006, the International Association of Physicians in AIDS Care will mark a decade of highly active antiretroviralA medication or other substance which is active against retroviruses such as HIV. therapy. Has it really been 10 years since the so-called Protease Moment? KIRSTY MACHON reports on where we have come from – and where to from here. read more »

The 13th annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the SMART study, but as usual, this important conference produced a great deal more than a single story. read more »